{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:47:00Z","timestamp":1769885220556,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05655-9","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T01:43:54Z","timestamp":1746495834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and urodynamic benefit of adding antimuscarinics after a loss of efficacy of intradetrusor botulinum toxin in patients with multiple sclerosis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9917-5799","authenticated-orcid":false,"given":"Adrien","family":"Haegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Chesnel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00eblys","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdaline","family":"Vivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Hentzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"5655_CR1","doi-asserted-by":"publisher","first-page":"103793","DOI":"10.1016\/j.msard.2022.103793","volume":"62","author":"TB Kaplan","year":"2022","unstructured":"Kaplan TB, Gopal A, Block VJ, Suskind AM, Zhao C, Polgar-Turcsanyi M, Saraceno TJ, Gomez R, Santaniello A, Consortium S, Ayoubi NE, Cree BAC, Hauser SL, Weiner H, Chitnis T, Khoury S, Bove R (2022) Challenges to longitudinal characterization of lower urinary tract dysfunction in multiple sclerosis. Mult Scler Relat Disord 62:103793. https:\/\/doi.org\/10.1016\/j.msard.2022.103793","journal-title":"Mult Scler Relat Disord"},{"key":"5655_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","volume":"15","author":"I Kister","year":"2013","unstructured":"Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J (2013) Natural history of multiple sclerosis symptoms. Int J MS Care 15:146\u2013158. https:\/\/doi.org\/10.7224\/1537-2073.2012-053","journal-title":"Int J MS Care"},{"key":"5655_CR3","doi-asserted-by":"publisher","first-page":"175628722211224","DOI":"10.1177\/17562872221122484","volume":"14","author":"E Andretta","year":"2022","unstructured":"Andretta E, Finazzi Agr\u00f2 E, Calabrese M, Orecchia L, Furlan A, Zuliani C (2022) Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data. Ther Adv Urol 14:17562872221122484. https:\/\/doi.org\/10.1177\/17562872221122484","journal-title":"Ther Adv Urol"},{"key":"5655_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","volume":"110","author":"A Wagg","year":"2012","unstructured":"Wagg A, Compion G, Fahey A, Siddiqui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767\u20131774. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11023.x","journal-title":"BJU Int"},{"key":"5655_CR5","doi-asserted-by":"publisher","unstructured":"Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 65. https:\/\/doi.org\/10.1007\/s00228-008-0600-9","DOI":"10.1007\/s00228-008-0600-9"},{"key":"5655_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11910-018-0857-z","volume":"18","author":"J Tornic","year":"2018","unstructured":"Tornic J, Panicker JN (2018) The management of lower urinary tract dysfunction in multiple sclerosis. Curr Neurol Neurosci Rep 18:54. https:\/\/doi.org\/10.1007\/s11910-018-0857-z","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5655_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrurol.2016.53","volume":"13","author":"V Ph\u00e9","year":"2016","unstructured":"Ph\u00e9 V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13:275\u2013288. https:\/\/doi.org\/10.1038\/nrurol.2016.53","journal-title":"Nat Rev Urol"},{"key":"5655_CR8","unstructured":"THE GUIDELINE - Uroweb In: Uroweb - Eur. Assoc. Urol. https:\/\/uroweb.org\/guidelines\/neuro-urology\/chapter\/the-guideline. Accessed 16 Apr 2024"},{"key":"5655_CR9","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/nau.23352","volume":"37","author":"C Joussain","year":"2018","unstructured":"Joussain C, Popoff M, Ph\u00e9 V, Even A, Bosset P-O, Pottier S, Falcou L, Levy J, Vaugier I, Chartier Kastler E, Schurch B, Denys P (2018) Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn 37:799\u2013806. https:\/\/doi.org\/10.1002\/nau.23352","journal-title":"Neurourol Urodyn"},{"key":"5655_CR10","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1177\/13524585231174580","volume":"29","author":"S Delaval","year":"2023","unstructured":"Delaval S, Dequirez P-L, Hentzen C, Baron M, Mille E, Tariel F, Peyronnet B, Perrouin-Verbe M-A, Pierache A, Chartier-Kastler E, Capon G, Cornu J-N, Castel-Lacanal E, Gam\u00e9 X, Karsenty G, Ruffion A, Denys P, Even A, Joussain C, Amarenco G, Ph\u00e9 V, Biardeau X (2023) Intravesical injections of botulinum neurotoxin A to treat overactive bladder and\/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French association of urology. Mult Scler Houndmills Basingstoke Engl 29:1024\u20131032. https:\/\/doi.org\/10.1177\/13524585231174580","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"5655_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","volume":"201","author":"M Baron","year":"2019","unstructured":"Baron M, Peyronnet B, Aubl\u00e9 A, Hascoet J, Castel-Lacanal E, Miget G, Le Doze S, Prudhomme T, Manunta A, Cornu J-N, Gam\u00e9 X (2019) Long-Term discontinuation of botulinum toxin A intradetrusor injections for neurogenic detrusor overactivity: A multicenter study. J Urol 201:769\u2013776. https:\/\/doi.org\/10.1016\/j.juro.2018.10.012","journal-title":"J Urol"},{"key":"5655_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41393-019-0411-0","volume":"58","author":"KP Hebert","year":"2020","unstructured":"Hebert KP, Klarskov N, Bagi P, Biering-S\u00f8rensen F, Elmelund M (2020) Long term continuation with repeated botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord 58:675\u2013681. https:\/\/doi.org\/10.1038\/s41393-019-0411-0","journal-title":"Spinal Cord"},{"key":"5655_CR13","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1007\/s00192-021-04676-3","volume":"32","author":"A Woll","year":"2021","unstructured":"Woll A, Edenfield A, Locke M, Swift S (2021) Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents. Int Urogynecol J 32:2803\u20132806. https:\/\/doi.org\/10.1007\/s00192-021-04676-3","journal-title":"Int Urogynecol J"},{"key":"5655_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.5213\/inj.1938098.049","volume":"23","author":"MA Elbaset","year":"2019","unstructured":"Elbaset MA, Taha D-E, El-Hefnawy AS, Zahran MH, Shokeir AA (2019) Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: A prospective blinded randomized trial. Int Neurourol J 23:240\u2013248. https:\/\/doi.org\/10.5213\/inj.1938098.049","journal-title":"Int Neurourol J"},{"key":"5655_CR15","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1097\/MJT.0000000000001531","volume":"29","author":"I Ciofu","year":"2022","unstructured":"Ciofu I, Ceausu I, Chirca NM, Persu C (2022) Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity. Am J Ther 29:e507\u2013e511. https:\/\/doi.org\/10.1097\/MJT.0000000000001531","journal-title":"Am J Ther"},{"key":"5655_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/bju.13976","volume":"120","author":"M Koschorke","year":"2017","unstructured":"Koschorke M, Leitner L, Sadri H, Kn\u00fcpfer SC, Mehnert U, Kessler TM (2017) Intradetrusor OnabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU Int 120:848\u2013854. https:\/\/doi.org\/10.1111\/bju.13976","journal-title":"BJU Int"},{"key":"5655_CR17","doi-asserted-by":"publisher","unstructured":"Tiryaki S, Tekin A, Avanoglu A, Franco I, Ulman I (2022) A pilot study assessing average detrusor pressure garnered from area under a urodynamic curve: evaluation of clinical outcomes. J Pediatr Urol 18. https:\/\/doi.org\/10.1016\/j.jpurol.2022.02.012. 325.e1-325.e9","DOI":"10.1016\/j.jpurol.2022.02.012"},{"key":"5655_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/nau.24158","volume":"38","author":"A Kasman","year":"2019","unstructured":"Kasman A, Stave C, Elliott CS (2019) Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature. Neurourol Urodyn 38:2083\u20132092. https:\/\/doi.org\/10.1002\/nau.24158","journal-title":"Neurourol Urodyn"},{"key":"5655_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","volume":"49","author":"A Apostolidis","year":"2006","unstructured":"Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644\u2013650. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.010","journal-title":"Eur Urol"},{"key":"5655_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0302-2838(02)00540-7","volume":"43","author":"K-E Andersson","year":"2003","unstructured":"Andersson K-E, Yoshida M (2003) Antimuscarinics and the overactive detrusor\u2013which is the main mechanism of action? Eur Urol 43:1\u20135. https:\/\/doi.org\/10.1016\/s0302-2838(02)00540-7","journal-title":"Eur Urol"},{"key":"5655_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","volume":"30","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert K-D, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C (2013) OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 30:819\u2013833. https:\/\/doi.org\/10.1007\/s12325-013-0054-z","journal-title":"Adv Ther"},{"key":"5655_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","volume":"47","author":"J Grosse","year":"2005","unstructured":"Grosse J, Kramer G, St\u00f6hrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653\u2013659. https:\/\/doi.org\/10.1016\/j.eururo.2004.11.009","journal-title":"Eur Urol"},{"key":"5655_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sc.2013.42","volume":"51","author":"E Finazzi-Agr\u00f2","year":"2013","unstructured":"Finazzi-Agr\u00f2 E, Topazio L, Perugia C, Lombardi G, Finita Celso M, De Nunzio C, Del Popolo G (2013) The use of Oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study. Spinal Cord 51:637\u2013641. https:\/\/doi.org\/10.1038\/sc.2013.42","journal-title":"Spinal Cord"},{"key":"5655_CR24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/nau.23501","volume":"37","author":"S Musco","year":"2018","unstructured":"Musco S, Padilla-Fern\u00e1ndez B, Del Popolo G, Bonifazi M, Blok BFM, Groen J, \u2019t Hoen L, Pannek J, Bonzon J, Kessler TM, Schneider MP, Gross T, Karsenty G, Ph\u00e9 V, Hamid R, Ecclestone H, Castro-Diaz D (2018) Value of urodynamic findings in predicting upper urinary tract damage in neuro-urological patients: A systematic review. Neurourol Urodyn 37:1522\u20131540. https:\/\/doi.org\/10.1002\/nau.23501","journal-title":"Neurourol Urodyn"},{"key":"5655_CR25","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/nau.24962","volume":"41","author":"DK Bowen","year":"2022","unstructured":"Bowen DK, Meyer T, Rosoklija I, Sturm R, Chu DI, Cheng EY, Yerkes EB (2022) Botulinum toxin in patients at-risk for bladder augmentation: durable impact or kicking the can? Neurourol Urodyn 41:1406\u20131413. https:\/\/doi.org\/10.1002\/nau.24962","journal-title":"Neurourol Urodyn"},{"key":"5655_CR26","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00192-021-04909-5","volume":"32","author":"V Duong","year":"2021","unstructured":"Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C (2021) A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J 32:2693\u20132702. https:\/\/doi.org\/10.1007\/s00192-021-04909-5","journal-title":"Int Urogynecol J"},{"key":"5655_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1177\/0269215509353252","volume":"24","author":"JN Panicker","year":"2010","unstructured":"Panicker JN, de S\u00e8ze M, Fowler CJ (2010) Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management. Clin Rehabil 24:579\u2013589. https:\/\/doi.org\/10.1177\/0269215509353252","journal-title":"Clin Rehabil"}],"updated-by":[{"DOI":"10.1007\/s00345-025-05972-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000}}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05655-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05655-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05655-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:50:32Z","timestamp":1767966632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05655-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5655"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05655-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00345-025-05972-z","URL":"https:\/\/doi.org\/10.1007\/s00345-025-05972-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}